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The salivary gland is an important tissue for persistence and transmission of multiple
viruses. Previous work showed that salivary gland tissue-resident CD8+ T cells elicited by
viruses were poorly functional ex vivo. Using a model of persistent murine cytomegalovirus
(MCMV) infection, we now show that CD8+ T cells in the salivary gland and other nonlymphoid tissues of mice express multiple molecules associated with T cell exhaustion
including PD-1, CD73 and CD39. Strikingly however, these molecules were expressed
independently of virus or antigen. Rather, PD-1-expressing T cells remained PD-1+ after
migration into tissues regardless of infection, while CD73 was activated on CD8+ T cells by
TGF-b signaling. Blockade of PD-L1, but not CD73, improved cytokine production by
salivary gland T cells ex vivo and increased the expression of granzyme B after stimulation
within the salivary gland. Nevertheless, salivary-gland localized CD8+ T cells could kill PDL1-expressing targets in vivo, albeit with modest efﬁciency, and this was not improved by
PD-L1 blockade. Moreover, the impact of PD-L1 blockade on granzyme B expression
waned with time. In contrast, the function of kidney-localized T cells was improved by
CD73 blockade, but was unaffected by PD-L1 blockade. These data show that tissue
localization per se is associated with expression of inhibitory molecules that can impact T
cell function, but that the functional impact of this expression is context- and
tissue-dependent.
Keywords: CD8 T cells, tissue-resident CD8+ T cell, PD-1, CD73, cytomegalovirus (CMV)

INTRODUCTION
Multiple viruses infect the salivary gland and are shed into saliva for transmission to new hosts,
including examples such as cytomegalovirus, Epstein Barr Virus, Human Herpesvirus 6, mumps
virus, rabies virus, and even SARS-CoV-2 (1–7). Thus, it is important to understand anti-viral T cell
behavior in the salivary gland and other sites of viral shedding.
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Many labs, including our own, have used the murine
cytomegalovirus (MCMV) model to study viral infection of the
salivary gland and the resulting T cell responses (8–16).
Cytomegalovirus is a member of the beta-subfamily of
herpesviruses that infects the majority of people world-wide.
Primary infection typically occurs through contact with infected
secretions (e.g. saliva, urine or breast milk), after which the virus
spreads systemically in the body of the new host (17). CMV
establishes latency in many cells throughout the body and is
never eradicated but is thought to undergo regular attempts to
reactivate and spread (18). Thus, the immune system, and T cells
in particular, must maintain continuous vigilance in order to
control CMV for the life of the host.
The prolonged virus/host dé tente leads to profound changes
to the T cell compartment of the host. In humans and mice,
CMV-speciﬁc CD8+ T cells in circulation are sustained at
high frequencies in an antigen-dependent manner, or even
accumulate over time in a process that has been called
“memory inﬂation” (18–24). Evidence suggests that these T
cells in mice and humans suppress viral gene expression and
control viral reactivation and viral spread (9, 25, 26).
Remarkably, while the ongoing stimulation causes marked
differentiation of CMV-speciﬁc T cells, the circulating T cells
remain functional effector cells that can suppress virus and do
not exhibit the phenotype, gene signature or functional defects
associated with T cell exhaustion including loss of cytokine
production and cytolytic capacity, and upregulation of immune
checkpoint molecules such as PD-1 (22, 26–31).
In contrast to most tissues in the body, HCMV replicates
persistently in sites of shedding including the salivary gland and
kidney, and is known to be shed in saliva and urine for prolonged
periods of time in humans (4, 32). Similarly, MCMV persistence
has been shown in the salivary glands and kidneys of mice (33,
34), although the salivary gland is commonly considered to be
the primary site of viral persistence in mice while shedding urine
has been much less studied and may be restricted to perinatal
infections (35). It is still unclear whether T cells in these sites of
viral persistence and shedding remain functional. Foundational
studies from Jonjic and colleagues demonstrated that MCMVspeciﬁc CD8+ T cells were unable to control MCMV in the
salivary gland (8, 36). Subsequent work showed that MCMVspeciﬁc CD8+ T cells migrated into the salivary gland where they
largely developed a tissue-resident memory (TRM) phenotype
(i.e. CD103+, CD69+) in a TGF-b-dependent manner (13, 14).
Viral immune evasion mechanisms clearly support viral titers
and persistence in the salivary gland by removing MHC-I from
infected epithelial cells (11, 37), implying that T cells are able to
affect viral growth. Moreover, CD8+ T cells can control viral
reactivation from latency in the salivary gland (9). However, T
cells in the salivary gland have been shown to be poor at
producing cytokines ex vivo after restimulation in both MCMV
and lymphocytic choriomeningitis virus (LCMV) models
(14, 38).
Because of the persistent replication of MCMV in the salivary
gland, and the apparent functional defects of T cells recovered
from the salivary gland, we evaluated T cells in this tissue for
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markers of T cell exhaustion. We found that MCMV-speciﬁc T
cells in multiple tissues, including the salivary gland and kidney
expressed PD-1, CD39 and CD73 at steady state, markers that
are associated with recent antigen stimulation and T cell
exhaustion. Remarkably, expression of these molecules was
independent of antigen and MCMV, but instead associated
with tissue localization. Blockade of the PD-L1, but not CD73,
improved the function of salivary gland-localized T cells. In
contrast, cells in the kidney were unaffected by PD-L1 blockade,
but displayed improved function after CD73 blockade. Thus,
tissue localization per se is associated with expression of
inhibitory molecules, but the functional impact of this
expression is context-dependent.

MATERIALS AND METHODS
Mice
In most cases, mice were originally purchased from Jackson labs
and bred in house. C57BL/6J (B6) mice were used for direct
infections adoptive transfer recipients. OT-Is on a B6
background (C57BL/6-Tg(TcraTcrb)1100Mjb/J) were bred to
congenic CD45.1 expressing mice (B6.SJL-PtprcaPepcb/BoyJ).
For some experiments, CD45.1+ OT-Is were bred onto a
RAG -/- (B6.129S7-Rag1 tm1Mom /J) background. OT-I mice
deﬁcient in the TGF-b-RII were kindly provided by Dr. Nu
Zhang (UT Health, San Antonio) and generated by breeding
ﬂoxed TGFbRII mice (B6;129-Tgfbr2tm1Karl/J) to mice expressing
the Cre recombinase from the distal LCK promoter (B6.Cg-Tg
(Lck-icre)3779Nik/J). By crossing these mice to CD45.1+ OT-Is
and intercrossing, we ultimately generated OT-I littermates that
differed at the CD45 locus and were either wild-type or TGF-bRII-/-. Splenocytes from CD45.2+ TGF-bRII-/- OT-Is were mixed
with splenocytes from wildtype OT-I littermates that expressed
both CD45.1 and CD45.2. The mixed splenocytes were then
transferred into CD45.1+ recipients. All experiments were
approved by the Institutional Animal Care and Use Committee
at Thomas Jefferson University.

Viruses and Infections
Viruses were grown and titered as described previously (39).
Mice were infected by the intraperitoneal (i.p.) route with 2x105
pfu of either K181-tfr-OVA, expressing a membrane bound
version of full-length OVA (40), and called MCMV-OVA here,
or K181 (wild type MCMV) as indicated in the ﬁgure legends.
Mice were considered chronically infected after 12 weeks. Viral
replication in the organs was determined by plaque assay (39,
41). To determine viral load in the organs, genomic DNA was
isolated with the Puregene Core A kit (Qiagen) and qPCR for the
E1 gene was performed as described previously (42, 43).

Adoptive Transfers
To seed naïve mice with OT-Is, 1000 splenocytes from congenic
OT-Is were transferred retro-orbitally into recipient mice one
day prior to infection. For in vitro activated OT-Is, splenocytes
from OT-I mice were cultured in T cell media (RPMI with 1%
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Pen/strep, 10% FBS and 0.05 mM b-mercaptoethanol) at a
concentration of 4x106 cells/ml with 1 mg/ml of the SIINFEKL
peptide. On day 3 of culture, cells were washed and either
injected into naïve recipient mice via the retro-orbital sinus, or
washed and cultured in T cell media for 3 additional days with 30
U/ml of IL-2, but with no peptide to generate PD-1low cells for
transfer into naïve recipient mice.

plating, cells were treated with 100 ng/ml of IFN-g to upregulate
PD-L1. The following day, DC2.4 cells were pulsed with 10 mg/ml
of peptide for 5-6 hours and were washed 3 times before T cells
were added. When blocking antibodies were used, they were used
at a ﬁnal concentration of 60 mg/ml and were added to the DC2.4
cells 30 minutes before the addition of T cells. T cells from salivary
gland and kidneys were isolated as described above. Spleen
homogenates were enriched for T cells by negative selection
with biotin labelled antibodies against CD4, CD19, Ter-119 and
MHCII and using MojoSort Streptavadin Nanobeads (Biolegend).
In all cases, T cells were added to peptide pulsed DC2.4s and
incubated for 5 hours at 37 degrees C in the presence of brefeldin
A and were subsequently stained for intracellular cytokines
and phospho-proteins using the BD Fix/Perm kit using the
manufacturers recommended protocol.

Antibody Blockades
For the PD-L1 blockades, mice were injected i.p. with 200 mg of
anti-PD-L1 (clone 10F.9.G2) or isotype control (clone LTF-2) in
100 mL of PBS every two days for a period of two weeks unless
otherwise indicated. For CD73 blockades, mice were injected i.p.
with 200 mg of anti-CD73 (clone TY/23) or isotype control (clone
2A3) every other day for two weeks. All antibodies for in vivo
blockades were purchased from Bio-X-Cell.

In Vivo Intracellular Cytokine Staining (ICS)

Isolation of Lymphocytes and
FACS Staining

An in vivo intracellular cytokine assay was based on a previously
published protocol (38). In brief, mice were injected i.v. with 200
mg of SIINFEKL and another 50 mg of SIINFEKL was injected
directly into the salivary gland. For intraglandular injections,
mice were anesthetized with isoﬂurane using a nose cone and the
salivary gland was located by palpating the neck area. A total of
50 ml of solution was injected into the salivary gland with roughly
half injected into each lobe. Mice were sacriﬁced 6 hours after
injection. Organs were harvested and processed in media
containing 1 mg/ml of brefeldin A and stained for intracellular
cytokines as normal. In some experiments, mice were injected i.v.
with CFSE simultaneously with peptide as described
previously (13).

Lymphocytes were isolated from the spleen and non-lymphoid
organs as described previously (23). In brief, salivary gland and
kidney homogenates were suspended in 40% Percoll and layered
over on top of a 55% and 75% layered Percoll gradient. Samples
were spun for 25 minutes at 600 x g and cells were collected from
the interface between the 55% and 75% layers. Staining for FACS
was done as before (13, 23), with the addition of antibodies
against PD-1 (clone 29F.1A12), 2B4 (clone m2B4(B6)458.1),
Lag3 (C9B7W), TIM-3 (B8.2.C12), CTLA-4 (clone UC10-4B9),
CD73 (clone TY/11.8) and CD39 (clone Duha59), CD160 (clone
7H1), IFN-g (clone XMG1.2), TNF-a (clone MP6-XT22),
CD107a (clone 1D4B), PD-L1 (clone 10F.9G2), E-cadherin
(DECMA-1), Granzyme B (clone QA16A02), Ki67 (B56),
pAKT (SDRNR), pS6 (cupk43k). All antibodies were
purchased from Biolegend or BD Biosciences. All intracellular
stains, including cytokines and phospho-proteins, were
performed after permeabilization with the BD Fix/Perm Kit
(BD Biosciences). For Ki-67, the BD Permeabilization Buffer
Plus was used for the nuclear permeabilization after the initial
ﬁxation/permeabilization. Tetramers loaded with B8R peptide
were provided by the National Institutes of Health Tetramer
Core Facility (http://tetramer.yerkes.emory.edu/) and used as
described (22). In all experiments, i.v. antibody labelling was
used to distinguish between vascular and parenchymal localized
CD8+ T cells as described previously (23). Throughout, data
from non-lymphoid organs show cells unlabeled by the i.v.
antibody, indicating their presence outside of the vasculature
of the organ. Splenic data include all T cells, regardless of i.v.
antibody labeling. Flow cytometry data was collected on a
Fortessa (BD Biosciences) and analyzed using FlowJo version
10 (Treestar). Histograms are shown as modal plots
for comparison.

In Vivo Killing Assay
For target cells, splenocytes were harvested from naïve mice and
resuspended at 107 cells/ml. Cells were pulsed with 1 mg/ml of
either the SIINFEKL or an irrelevant peptide (B8R) at 37 degrees
for one hour. Cells pulsed with the SIINFEKL peptide were
labelled with 1 mM Cell trace far red while cells pulsed with the
B8R peptide were labelled with 5 mM CFSE. Peptide pulsed
populations were mixed and injected i.v. and i.g. into mice. Mice
were sacriﬁced after 48 hours and half of each organ was used to
isolate lymphocytes for FACS analysis. The remaining half of
each organ was frozen in OCT media for histological sectioning.
Sections were prepared and stained with an antibody against Ecadherin (clone DECMA-1) and DAPI as described previously
(13). Images were captured on a Nikon Eclipse E800 with NIS
Elements Imaging Software and analyzed with Image J (45).

Statistical Analyses
Throughout data are shown as a mean of a group. In most cases,
data were pooled from multiple independent experiments and
combined for the graph. In these cases, error bars indicate the
standard error of the mean. In some cases, a representative
experiment consisting of multiple mice is shown if, for example,
batch effects were apparent or different protocols were used. In
these cases, error bars indicate the standard deviation of the
group. Animal numbers, whether the data were pooled from
multiple experiments, and the number of independent replicate

In Vitro Intracellular Cytokine Staining
In vitro stimulation for intracellular cytokine staining was done
as described previously (44) with minor modiﬁcations. Brieﬂy,
5x105 DC2.4s (kindly provided by Dr. Aron Lukacher) were
plated into each well of a ﬂat-bottom 96 well plate. 4 hours after
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experiments are indicated in the ﬁgure legends. Statistical
signiﬁcance was assessed with pairwise comparisons between 2
groups using either paired or unpaired two-tailed students’ ttests, or a one sample t-test, as appropriate and indicated in the
ﬁgure legends. In all cases, asterisks indicate p-value thresholds
as follows: *p ≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.

detect elevated levels of CTLA4, TIM3, LAG3, or CD160 on
salivary gland-localized MCMV-speciﬁc T cells when compared
to their counterparts in the spleen (not shown). Importantly, a
similar phenotype was evident on MCMV-speciﬁc T cells
identiﬁed by tetramer staining after infection with the K181
strain of MCMV (Supplemental Figure 4). Therefore, this is not
an OT-I or MCMV-OVA-related phenomenon.

RESULTS

Inhibitory Molecule Expression on TissueLocalized T Cells Is Antigen Independent

Multiple Inhibitory Molecules
Expressed on MCMV Speciﬁc
Tissue-Resident T Cells

PD-1 has been identiﬁed on TRM populations or tissue-localized T
cells in some tissues (44, 50–53), and it is unclear whether this is
associated with local antigen. However, it is well-known that PD1 and CD39 are both expressed on recently-activated T cells and
both are markers of chronic antigen exposure and functional
exhaustion (54–57). The MCMV-OVA strain we used is highly
attenuated for salivary gland infection compared to wild-type
MCMV (40, 58) and therefore would seem unlikely to drive T cell
exhaustion. Nevertheless, it does reach the salivary gland and
persist there. Thus, it was possible that MCMV-speciﬁc T cells in
tissues might be driven to express inhibitory molecules as a result
of MCMV persistence. To test this, mice were infected with
Vaccinia virus (VV), a non-persistent DNA virus, and were
sacriﬁced at least 1 month post infection. T cells speciﬁc for the
VV epitope B8R were identiﬁed by tetramer staining.
Remarkably, expression of PD-1, CD39, CD73 and 2B4 was
generally similar between MCMV-speciﬁc and VV-speciﬁc T
cells including intermediate expression of PD-1 and coexpression of CD39 and CD73 in multiple organs (Figures 2A–
C). These data suggest that elevated expression of these molecules
is not associated with viral persistence or latency and not
dependent on the type of virus or the speciﬁcity of the T cells.
To conﬁrm the conclusion that expression of inhibitory
molecules was independent of antigen persistence, uninfected
mice were seeded with in vitro-activated OT-I T cells, which we
have previously shown can become TRM in the salivary gland
after adoptive transfer (15). Even without an infection, the
transferred OT-I T cells that reached the salivary gland, kidney
and other non-lymphoid organs expressed higher levels of PD-1,
CD39 and CD73 than their counterparts in the spleen
(Figures 2D, E). Together, these data show that expression of
PD-1, CD39 and CD73 is not sustained by persistent antigen, but
instead is associated with tissue-localization.

To study tissue-localized T cells, mice were seeded with
congenically marked OT-Is one day before infection with
MCMV-OVA and sacriﬁced more than three months post
infection. In all experiments, ﬂuorochrome labelled CD8a
antibody was injected intravenously immediately prior to
sacriﬁce to distinguish between cells in the vasculature and
cells in the parenchyma of the organs. Salivary gland-localized
OT-Is expressed elevated levels of PD-1 when compared to
OT-Is in the spleen (Figure 1A, see representative gating
strategy in Supplemental Figure 1). Surprisingly, this
expression of PD-1 was replicated throughout the body on
tissue-localized MCMV-speciﬁc T cells. Indeed, MCMV
speciﬁc T cells in the parenchyma, but not the vasculature, of
the kidney, mammary gland, female reproductive tract and the
small intestine (lamina propria and intra-epithelial lymphocytes)
all expressed elevated levels of PD-1, similarly to the
salivary gland (Figure 1B). While PD-1, was expressed on
nearly all cells in the salivary gland, expression was strongest
on cells that expressed the TRM phenotype of CD103 and CD69
(Supplemental Figures 2A, B). Mean ﬂuorescence of PD-1 and
the frequency of PD-1 expression was highest on T cells in the
salivary gland compared to other organs (Figure 1C and
Supplemental Figure 2C). Nevertheless, these levels were
intermediate when directly compared to a population of
functionally exhausted tumor-speciﬁc T cells (Supplemental
Figure 2D). Notably, expression of full-length PD-1 by sorted
salivary gland OT-Is was conﬁrmed by PCR of cDNA (not
shown) as previously described (46). Analyses of T cells over
time showed that PD-1 expression was lost from splenic T cells
within 3 weeks of infection, as expected, but sustained on salivary
gland-localized T cells (Figure 1D, p<0.0001 at >12 weeks post
infection). Kidney-localized T cells lost PD-1 expression
compared to salivary gland-localized T cells (p<0.0001), but
sustained higher levels of PD-1 when compared to splenic
T cells (Figure 1D, p<0.0001).
MCMV speciﬁc CD8+ T cells from the salivary gland and
other tissues also expressed the adenosine producing enzymes
CD39 and CD73 (Figures 1A, E). Like PD-1, expression of CD73
and CD39 was strongest on cells that expressed CD103 and
CD69 (Supplemental Figure 2A). Finally, OT-Is in the salivary
gland that expressed CD103 also co-expressed 2B4 (CD244), as
has been previously reported for T cells in other tissues (47–49)
(Figure 1A and Supplemental Figure 3). In contrast, we did not
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TGF-b Is Responsible for CD73
Expression, But Not CD39 or
PD-1 Expression
TGF-b is known to be important for the tissue-resident T cell
program, including expression of CD103 (59–62). Moreover,
CD73-expression has been previously linked to TGF-b signaling
(63). Previous work from our lab has shown that TGF-b is
constitutively expressed in the salivary gland, even without
infection (15) and the Oxenius lab reported that it is essential
for normal TRM numbers in the salivary gland after MCMV
infection (14). Thus, we tested the impact of TGF-b signaling on
PD-1, CD39 and CD73 expression on T cells in the salivary gland
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FIGURE 1 | Expression of inhibitory molecules on MCMV speciﬁc T cells in the salivary gland. Mice were seeded with OT-Is and infected with MCMV-OVA. At least
3 months post infection mice were injected i.v. with ﬂuorochrome labeled anti-CD8a antibody and sacriﬁced 3 minutes later. (A) Representative FACS plots show
inhibitory molecule expression on i.v. antibody-negative salivary gland OT-Is (grey histograms) compared to total (i.v. negative and i.v. positive combined) spleen
derived OT-Is from the same animal (open histograms, n=5 from 3 independent experiments). (B) Representative FACS plots of OT-Is isolated from the indicated
organs showing PD-1 expression relative to staining by the intravenously injected CD8a antibody. (C) Mean ﬂuorescence intensity of PD-1 staining on OT-Is from the
indicated organs, (n=6-9 mice from 3 experiments). Data show the mean of all mice and error bars show the standard error of the mean. (D) Frequency of PD-1
expression on OT-Is from the spleen, salivary gland and kidney over time (n=6-11 from 2-4 independent experiments at each time point). Horizontal lines represent
the mean and error bars show the standard error of the mean. (E) Frequency of CD73 and CD39 expression on OT-Is isolated from the indicated organs, (n=4-13
from 4 independent experiments). Data show the mean of all mice and error bars show the standard error of the mean. Statistical signiﬁcance in all cases, was
tested by direct comparisons between pairs of organs using paired, two-tailed student’s t-tests. For simplicity and clarity, shown are signiﬁcant differences between
spleen and other organs. *p ≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.

and kidney. To this end, OT-I T cells lacking the TGF-b-RII
were mixed with congenic wild type OT-I T cells from litter mates
and co-transferred into mice that were subsequently infected with
MCMV-OVA. In agreement with the data from the Oxenius lab,
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lack of the TGF-b-RII on OT-Is reduced their frequency in
the salivary gland relative to wild-type cells and eliminated
expression of CD103 (Supplemental Figures 5A, B).
Interestingly, TGF-b-RII-/- OT-Is were not under-represented in
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FIGURE 2 | MCMV-independent and antigen-independent expression of inhibitory molecules on tissue-localized T cells. Mice were infected with Vaccinia and virus
speciﬁc CD8s were identiﬁed by B8R tetramer more than 1 month post infection. (A) Representative FACS plots show PD-1 expression on i.v. antibody-negative
B8R speciﬁc T cells in the indicated non-lymphoid organ (grey histograms) compared to all T cells in the spleen (open histograms). (B) Mean ﬂuorescence intensity of
PD-1 on B8R speciﬁc cells from the indicated organs. Data show the mean of n=8 mice from 2 independent experiments and error bars show the standard error of
the mean. (C) Frequency of CD73 and CD39 expression on B8R speciﬁc T cells from the indicated organs. Data show the mean of n=3 mice from one experiment
and the error bars show the standard deviation of the group. (D) OT-Is were activated with peptide in vitro for 3 days before adoptive transfer into naïve mice, which
remained uninfected after transfer. OT-Is recovered from the indicated organs 2 weeks after transfer. Data show the mean ﬂuorescence intensity of PD-1 from
recovered OT-I cells (n=3 mice per group from one experiment, representative of 3 independent experiments with 11 mice total) and the error bars show the
standard deviation of the group. (E) OT-Is from the experiment in “D” were analyzed for expression of CD73 and CD39. Shown is the frequency of CD73 and CD39
expression on OT-Is isolated from the indicated organs from n=3 mice per group. Error bars represent the standard deviation of the group. Statistical signiﬁcance in
(B–E) was tested by direct comparisons between pairs of organs using paired, two-tailed student’s t-tests. As in Figure 1, shown are signiﬁcant differences
between spleen and other organs for the MFI of PD-1 (B, D) or the frequency of cells expressing both CD73 and CD39 (C, E). *p≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001.

the kidney (Supplemental Figure 5A), where the development
of the TRM phenotype is much less apparent (13). Strikingly
however, the frequency of CD73 on OT-Is was severely reduced
on TGF-b-RII KO OT-Is compared to wild type OT-Is in all
organs tested (Figure 3A). In contrast, the loss of TGF-b signaling
only had a mild and not statistically signiﬁcant impact on the
expression of CD39 (Figure 3B) and PD-1 (Figure 3C).
Previous work from our lab has shown that T cells only trafﬁc
to, and become resident in, the salivary gland when they have

Frontiers in Immunology | www.frontiersin.org

been recently stimulated by antigen (13). This raises the question
of whether the tissue environment is causing an upregulation of
PD-1 or if instead, PD-1 is already expressed by recentlystimulated cells arriving in the gland and then being retained.
To test this, we compared OT-I T cells that expressed high or low
levels of PD-1 prior to transfer into naïve, uninfected mice. We
have previously shown that activated T cells can reach the
salivary gland in naïve, uninfected recipients (15). OT-I T cells
lacking RAG1 were speciﬁcally used in this experiment to rule
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FIGURE 3 | TGF-b induces CD73 expression on CD8+ T cells, but PD-1 is sustained by tissue localization. (A–C) Mice were seeded with a mixture of wild type (WT)
and TGFbII receptor KO OT-Is and infected with MCMV-OVA. Mice were sacriﬁced at least 1 month post infection. Expression of (A) CD73 (B) CD39 and (C) PD-1
on OT-Is from the indicated organs. Lines connect TGFbII receptor KO OT-Is and WT OT-Is from the same mice. Data were analyzed with paired t-tests to assess
differences between WT and KO cells recovered from the indicated organ of each animal and to compare cells between organs of the same animal (n=7 mice pooled
from 2 independent experiments). (D, E) PD-1high OT-Is were generated by seeding mice with RAG-/- OT-Is, infecting recipients with MCMV-OVA and harvesting T
cells on day 7. PD-1low populations differing at the CD45 locus were generated by activating RAG-/- OT-I T cells in vitro with peptide for three days and then resting
for three days without peptide stimulation. PD-1high and PD-1low populations were mixed and adoptively transferred into naïve mice. (D) Representative FACS plots
of PD-1 expression on the in vivo (PD-1high) and in vitro (PD-1low) generated T cells just before adoptive transfer and again, on i.v. antibody-negative OT-Is after
recovery from the salivary gland two weeks after adoptive transfer. (E) Mean ﬂuorescence intensity of PD-1 expression on OT-Is recovered from recipient mice two
weeks after transfer. Lines connect the two different OT-I populations recovered from the same recipients. Data were analyzed with paired t-tests to assess
differences between WT and KO cells recovered from the indicated organ of each animal and to compare cells between organs of the same animal (n=6 mice pooled
from 2 independent experiments) *p ≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.

Blocking PD-L1 Receptors Improves the
Function of Salivary Gland T Cells Ex Vivo

out the possibility that endogenous TCR-a chains might lead to
cross-reactivity with antigens in the mouse. To generate PD-1high
OT-Is, we seeded mice with RAG-/- OT-Is, infected the recipients
with MCMV-OVA, and isolated OT-I T cells from the spleens of
mice 7 days later, a time at which they express high levels of
PD-1. As a comparison, we generated a PD-1low population by
activating congenic RAG-/- OT-I T cells in vitro with peptide for
three days and then resting the cells for three days without
peptide stimulation. These two populations were mixed and cotransferred into naïve mice. The difference in PD-1 expression
when these cells were mixed for transfer is shown in Figure 3D.
Two weeks later, each population retained different levels of PD1 in the salivary gland, kidney and spleen (Figures 3D, E). Most
strikingly, the retention of PD-1 was signiﬁcantly greater in the
salivary gland and kidney in comparison with the spleen.
Together, these data suggest that the tissue environments of
the salivary gland and kidney promote retention of PD-1 on T
cells, independently of virus or antigen, while CD73 expression is
induced by TGF-b after cells arrive.
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To determine if constitutive inhibitory molecule expression had an
impact on T cell function, we isolated OT-Is from the organs of
MCMV-infected mice (>12 weeks after infection) and stimulated
them ex vivo on peptide pulsed DC2.4s (PD-L1+, not shown) in
the presence or absence of a PD-L1 blocking antibody. Notably, we
puriﬁed these T cells through a discontinuous Percoll gradient as
previously described (23). This puriﬁcation and the use of antigen
presenting cells (APCs) resulted in increased function compared
to T cells stimulated in the salivary gland homogenate (not
shown), which was the protocol used in a previous study by
Hofmann and Pircher (38). Nevertheless, OT-Is isolated from the
salivary gland produced IFN-g and degranulated at signiﬁcantly
lower frequencies than OT-Is isolated from the spleen
(Figures 4A–C). Preventing OT-Is from engaging with PD-L1
during antigen encounter slightly improved the production of
TNF-a and degranulation (Figures 4B, C). Boolean gating of T
cells producing IFN-g, TNF-a and exposing CD107a revealed that
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FIGURE 4 | Impact of blocking PD-L1 on T cell function ex vivo. (A–E) Mice were seeded with OT-Is and infected with MCMV-OVA. At least 3 months post infection
OT-Is were harvested from the indicated organs as described in the materials and methods, and stimulated for 5 hours with SIINFEKL pulsed DC2.4s, in the
presence of anti-PD-L1 or isotype control antibody (iso). (A) Frequency of OT-Is that produced IFN-g, or (B) co-produced IFN-g and TNF-a or (C) produced IFN-g
and exposed CD107a during stimulation. Each line connects OT-Is from the same mouse (n=7 mice pooled from 3 independent experiments). Data were analyzed in
pairwise fashion using paired, two-tailed t-tests to assess differences between cells recovered from different organs of the same mouse, or cells recovered from a
single organ and restimulated with or without blocking antibody. (D) Boolean gating of OT-Is from (A–C) expressing IFN-g, TNF-a and/or CD107a after stimulation,
(n=7 from 3 independent experiments). Populations expressing 1, 2, and/or 3 functions were analyzed by paired two-tailed t-tests. (E) Fold change in mean
ﬂuorescence intensity of the indicated marker of anti-PD-L1 treated OT-Is relative to isotype control treated samples from samples in (A–D). In order to compare the
MFI of the indicated molecule across experiments, the data was plotted as the ratio between cells treated with the PD-L1 blocking antibody vs cells treated with the
isotype control antibody. Therefore, a value of 1 would indicate no change between treated and control wells. Statistical tests were conducted using one sample ttests between each condition and a hypothetical value of 1 (n=7 mice from 3 independent experiments). (F) Mice were seeded with OT-Is and infected with MCMVOVA. At least 3 months after infection, mice were treated with anti-PD-L1 blocking antibody or isotype control antibody for 2 weeks. Lymphocytes were isolated
from the indicated organs and stimulated for 5 hours with SIINFEKL pulsed DC2.4s in the presence of the same antibody that was injected into the mice. The data
show Boolean gating of IFN-g, TNF-a and CD107a expression by OT-Is after stimulation. Since cells were derived from different mice treated with isotype control
antibody or PD-L1 blocking antibody, populations expressing 1, 2, and/or 3 functions were analyzed by unpaired two-tailed t-tests. Data are from n=3 mice,
representative of 2 independent experiments, n=6. *p ≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, n.s., not signiﬁcant.
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salivary gland-localized T cells at early times post infection, when
there is still virus replicating in the salivary gland. However,
blockade of CD73 from day 7 to 21 after infection also failed to
improve the function of salivary gland T cells (not shown).
Together, these data suggest that T cells localized to the salivary
gland, spleen and kidney were differentially impacted by PD-1
and adenosine production: salivary gland localized T cells were
inhibited by PD-1 (Figure 4), while T cells in the kidney were
inhibited by CD73 (Figure 5F).

including the PD-L1 blocking antibody in the stimulation culture
modestly improved the overall function of the T cells from the
salivary gland (Figure 4D). Consistent with this, T cells also
exhibited an increased mean ﬂuorescence intensity of TNF-a
when PD-L1 was blocked during stimulation, relative to the
same cells stimulated without PD-L1 blockade (Figure 4E).
Moreover, blocking PD-L1 also increased the phosphorylation of
molecules AKT and S6, which are downstream of TCR signaling
and have been shown to be modulated by PD-1 signaling during T
cell activation (64, 65). These data show that the intermediate
levels of PD-1 that are constitutively present on salivary gland T
cells are sufﬁcient to reduce the strength of TCR signaling and
modestly inhibit effector functions.
We considered the possibility that T cell function would be
more markedly altered by treating the mice with PD-L1 blocking
antibody before T cells were extracted and stimulated. To this
end, we treated MCMV-infected mice (>12 weeks post-infection)
with a PD-L1 blocking antibody or an isotype control antibody
for two weeks. The i.p. injected blocking antibody inﬁltrated
non-lymphoid organs and blocked PD-L1, as assessed by
staining harvested tissues ex vivo with a ﬂuorescently labelled
version of the same anti-PD-L1 antibody clone used for blocking
(Supplemental Figure 6). OT-Is were isolated from the spleen,
salivary gland and kidney and were maintained in the presence
or absence of the blocking antibody during restimulation. In this
setting, blocking PD-L1 also resulted in a signiﬁcant increase in
cells that were double or triple positive (Figure 4F). These data
suggest that ongoing PD-L1 signaling in the animal contributes
to the reduction of T cell functionality in the salivary gland. In
contrast, the function of kidney derived OT-Is was not altered by
the PD-L1 blockade (Figure 4F), despite their expression of
PD-1 (Figures 1–3).

Inhibitory Molecules Don’t Inﬂuence Cell
Number or Phenotype or Viral Control in
the Salivary Gland
During the course of these experiments, we were surprised to
note that PD-L1 or CD73 blockade had no impact on the number
of antigen speciﬁc CD8+ T cells or on the phenotype of those cells
in mice that had been infected for more than 12 weeks with
MCMV (Figures 6A–C). Similarly, there was no signiﬁcant
impact on OT-I number or phenotype when mice were treated
with blocking antibodies targeting PD-L1 or CD73 – separately
or in combination – between day 7 and day 21 of infection
(Supplemental Figures 7A–C). We have previously shown that
MCMV speciﬁc CD8 T cells in the salivary gland stop dividing
earlier than their counterparts in the spleen (13). However,
blocking PD-L1 did not reverse this result (Figure 6D).
Finally, the salivary gland is considered the primary site of
MCMV persistence in mice and CD8+ T cells selectively fail to
control the virus in this organ (8), at least in part due to viral
reduction of MHC-I antigen presentation on infected cells (11,
37) and the production of IL-10 (66). We wondered whether the
inhibitory molecules expressed by salivary gland-localized T cells
also contributed to their inability to clear MCMV from this
organ. Therefore, we assessed the impact of PD-L1 or CD73
blockade on viral load in the salivary gland. However, neither
viral genome copies (Figure 6E) nor viral replication
(Supplemental Figure 7E) in the salivary gland were impacted
by antibody blockades at early times after infection. Depleting
CD4+ T cells, which are known to play a role in controlling viral
replication in the salivary gland, also did not reveal an impact of
the PD-L1 blockade (Supplemental Figures 7D, E).

CD73 Blockade Improves T Cell Function
in the Kidney and Spleen, But Not the
Salivary Gland
To assess the impact of enzyme-mediated adenosine production,
we repeated the previous set of experiments using a CD73
blocking antibody. Adding anti-CD73 antibody during ex vivo
stimulation failed to improve the frequency of cells from any
tissue to produce cytokines or degranulate, and in fact, slightly
reduced the function of OT-Is from the spleen (Figures 5A–C)
resulting in a signiﬁcant increase in cells with only a single
function after stimulation and a decrease of cells with two or
three functional responses (Figure 5D). Similarly, blocking
CD73 failed to increase the mean ﬂuorescence of cytokines
produced by stimulated cells or the phosphorylation of AKT
and S6 (Figure 5E). Thus, CD73 blockade did not seem to
impact the strength of TCR signaling or increase effector
functions upon ex vivo stimulation. Interestingly however,
when anti-CD73 was administered to mice for 2 weeks prior to
T cell isolation and in vitro stimulation, OT-I T cells from the
kidney and spleen, but not the salivary gland, displayed
improved function (Figure 5F). Adenosine production via
CD39 and CD73 is dependent on the presence of extracellular
ATP, which is released upon cell death and stress. Therefore, we
wondered if a CD73 blockade would have more of an impact on

Frontiers in Immunology | www.frontiersin.org

Inhibitory Molecules Don’t Improve
Salivary Gland T Cell Function After
Intravenous Peptide Injection
Previous work showed that salivary gland-localized T cells were
more functional when stimulated in vivo by intravenously
injected peptide, compared to assays in which those T cells
were isolated and stimulated ex vivo (38). In agreement with this
work, the majority of salivary-localized CD8+ T cells (~80%)
produced IFN-g, with or without TNF-a, upon i.v. peptide
injection (Figure 6F). However, this approach did not fully
rescue T cell function. Cells in the salivary gland and kidney
were still less likely to produce both IFN-g and TNF-a when
compared with their counterparts from the spleen, and blockade
of either PD-L1, CD73 or both, for two weeks prior to peptide
injection did not change these results (Figure 6F). It was possible
that i.v. peptide injection drove T cells to migrate into the
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FIGURE 5 | Impact of blocking CD73 on T cell function ex vivo. (A–E) Mice were seeded with OT-Is and infected with MCMV-OVA. At least 3 months post infection
OT-Is were harvested from the indicated organs and stimulated for 5 hours with SIINFEKL pulsed DC2.4s in the presence of anti-CD73 or and isotype control
antibody (iso). (A) Frequency of OT-Is that produced IFN-g, or (B) co-produced IFN-g and TNF-a or (C) produced IFN-g and exposed CD107a during stimulation.
Each line connects OT-Is from the same mouse. Data were analyzed in pairwise fashion using paired, two-tailed t-tests to assess differences between cells
recovered from different organs of the same mouse, or cells recovered from a single organ and restimulated with or without blocking antibody, (n=4 from 2
independent experiments). (D) Boolean gating of OT-Is expressing IFN-g, TNF-a and/or CD107a after stimulation. Populations expressing 1, 2, and/or 3 functions
were analyzed by paired two-tailed t-tests. (n=4 from 2 independent experiments). (E) Fold change in mean ﬂuorescence intensity of the indicated marker of antiCD73 treated OT-Is relative to isotype control antibody treated controls from the cells shown in (A–C). As in Figure 4, the MFI of the indicated molecules were
compared across experiments as the ratio between cells treated with the blocking antibody vs cells treated with the isotype control antibody. Therefore, a value of 1
indicates no change between treated and control wells. Statistical comparisons were conducted using one sample t-tests between each condition and a hypothetical
value of 1 (n=4 from 2 independent experiments). (F) Mice were seeded with OT-Is and infected with MCMV-OVA. At least 3 months after infection, mice were
treated with anti-CD73 blocking antibody or isotype control for 2 weeks. Lymphocytes were isolated from the indicated organs and stimulated for 5 hours with
SIINFEKL pulsed DC2.4s in the presence of the same antibody that was injected into the mice. Shown is Boolean gating of OT-Is expressing IFN-g, TNF-a and/or
CD107a after stimulation. Since cells were derived from different mice treated with isotype control antibody or CD73 blocking antibody, populations expressing 1, 2,
and/or 3 functions were analyzed by unpaired two-tailed t-tests. Data are from n=6 mice from 2 independent experiments). *p ≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001, n.s., not signiﬁcant.

Importantly, peptide injection did not lead to an inﬂux of CFSElabeled CD8+ T cells into the salivary gland or kidney during the
course of the experiment (Supplemental Figure 7F), showing
that any cytokine expressing cells identiﬁed in this assay were
lodged in the tissue at the time of peptide injection.

salivary gland, which could obscure the function of T cells that
had been lodged in the salivary gland. To test this, we
simultaneously injected both CFSE and peptide intravenously.
We have previously shown that intravenous injection of CFSE
labels CD8+ T cells in circulation, but not the salivary gland (13).

Frontiers in Immunology | www.frontiersin.org

10

July 2021 | Volume 12 | Article 704862

Smith and Snyder

Inhibitory Molecules on Tissue CD8s

A

B

C

D

F
E

FIGURE 6 | Blocking PD-L1 or CD73 has minimal impact on in vivo maintenance, phenotype or function of T cells. (A–C) Mice were seeded with OT-Is and infected
with MCMV-OVA for at least 3 months, and then treated with the indicated blocking antibodies or isotype control (iso) for 2 weeks before sacriﬁce. The data show
cells recovered from the indicated organs after antibody treatment including: (A) the absolute numbers of OT-Is, (B) the frequency of CD69 and CD103 expression
by OT-Is, and (C) the frequency of KLRG-1 expression by OT-Is, (n=18 from 5 independent experiments). (D) Mice were infected with wild type MCMV and treated
with anti-PD-L1 blocking antibody for one week starting on day 7 of infection. Mice were sacriﬁced on day 14 and MCMV speciﬁc CD8s were identiﬁed by tetramer
staining. The data show the frequency of Ki-67 expression among M38-speciﬁc CD8s, (n=6 from 2 independent experiments). (E) Mice were infected with wild type
MCMV and treated with the indicated blocking antibodies for two weeks starting on day 7 of infection. Mice were sacriﬁced on day 21 and viral DNA load was
determined in the indicated organs by qPCR. Shown are the copies of viral genome per ug of DNA, (n=6 from 2 independent experiments). (F) Mice were seeded
with OT-Is and infected with MCMV-OVA for at least 3 months, and then treated with the indicated blocking antibodies for 2 weeks. Following antibody treatment,
mice were injected with SIINFEKL peptide (200 mg i.v and 50 mg directly into the salivary gland). Six hours after peptide injection, mice were sacriﬁced and organs
were collected and processed in media containing brefeldin A. Shown is the frequency of IFN-g and TNF-a producing OT-Is that were recovered. For comparison of
cells from different organs of the same mice, paired two-tailed t-tests were used. For comparison of cells in the same organ but from different mice with different
treatments (e.g. blockade or isotype control antibody) populations were analyzed by unpaired two-tailed t-tests. Data are from n=6 mice from 2 independent
experiments. *p ≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.

Intraglandular Injections of PD-L1Expressing Targets Reveals a Functional
Role of PD-1 on Salivary Gland T Cells
In Vivo

and kidney as it is in the spleen, and the cells that do express PDL1 are primarily (but not exclusively) of hematopoietic origin
(Figures 7A, B). Moreover, only a minor fraction of E-cadherin
expressing epithelial cells in the salivary gland expressed PD-L1
in both infected and naïve mice (Figure 7B). Since acinar
epithelial cells are an important site of MCMV replication and
persistence, these data suggest that many of these targets may
lack PD-L1. Therefore, we tested whether PD-1 altered the ability
of salivary gland-localized T cells to kill PD-L1-expressing

One possible explanation for the discrepancy between our ex vivo
stimulation results (Figures 4, 5) and the results obtained after
in vivo injection of peptide (Figure 6E) may be that responding
T cells are encountering antigen on cells that lack PD-L1 in vivo.
Indeed, PD-L1 is not expressed as highly in the salivary gland
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FIGURE 7 | T cell stimulation by PD-L1 expressing target cells. (A, B) Organs from naïve mice and mice infected with wildtype MCMV for 7 days were homogenized
as described in the methods, and directly stained for PD-L1 expression without Percoll isolation. (A) Representative FACS plots of PD-L1 expression on all cells
recovered from salivary glands. (B) Frequency of PD-L1 expression on different subtypes of cells in the indicated organs. Data are representative of 3 mice per
group. (C–E) Mice bearing OT-Is and infected with MCMV-OVA for either 21 days, or more than 12 weeks, received the PD-L1 blocking antibody or an isotype
control antibody for two weeks. At the end of the blocking period, splenocytes from naïve mice were pulsed with either SIINFEKL or an irrelevant peptide (B8R) and
labelled with CellTrace Far Red or CFSE respectively. Target cells were injected i.v. and intra-glandularly into 48 hours after target cell injection, tissues were
harvested for analyses. Half of the harvested organs were used to extract lymphocytes for FACS analysis and half were frozen for immunoﬂuorescent histology.
Shown is the frequency of (C) granzyme B expression and (D) Ki-67 expression by salivary gland localized OT-Is as assessed by FACS. In all cases, data were
analyzed in pairwise fashion between groups of mice treated or not with the PD-L1 blocking antibody using unpaired, two-tailed t-tests. (E) Speciﬁc killing of peptide
pulsed splenocytes contained withing E-cadherin+ regions of the salivary gland as assessed by histology (n=6-11 mice from 4 independent experiments). *p ≤0.05,
**p≤0.01, ***p≤0.001, ****p≤0.0001.

these targets. Mice were sacriﬁced 48 hours after i.g. injections.
This protocol allowed us to assess the activation of the salivary
gland-localized OT-I T cells and speciﬁc killing of the peptidepulsed targets, but did not allow for the assessment of cytokine
production by the T cells. First, we noted that salivary gland

targets. Through multiple experiments, we were unable to obtain
sufﬁcient numbers of T cells from the salivary gland to make
ex vivo killing assays reproducible. Therefore, we pulsed splenocytes
with the SIINFEKL peptide and injected them directly the
salivary gland (intraglandular injection – i.g.) to assess killing of
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Salivary gland-localized T cells are modestly inhibited by PD-1
expression in vivo. In contrast, kidney-localized T cells were
unaffected by PD-1, but modestly inhibited by CD73.

T cells expressed signiﬁcantly lower levels of granzyme B
compared to their counterparts in the spleen (Supplemental
Figure 8A). However, OT-Is responded to the injection of
peptide-pulsed targets by robustly upregulating granzyme B
(Figure 7C) and by upregulating the division marker Ki-67
(Figure 7D). Blocking PD-L1 signiﬁcantly increased the
upregulation of granzyme B (Figure 7C) and seemed to
enhance Ki-67 expression (Figure 7D) by T cells in mice that
had been infected for 21 days, but not in mice that were infected
for more than 12 weeks. Treating mice with both anti-CD73 and
anti-PD-L1 had no additional impact on granzyme B or division
(Supplemental Figures 8A, B).

DISCUSSION
The salivary gland and kidneys are major sites of shedding for
CMV and other viruses, and important tissues for viral spread to
new hosts. In humans and mice, CMV replicates persistently in
both tissues and infectious virus can be detected in the saliva of
mice and both saliva and urine of humans for prolonged periods
of time (4, 33, 67). It is possible that tissue-localized immune
regulation is exploited by CMV and other viruses to persist in
these tissues. Our data revealed that expression of inhibitory
molecules PD-1, CD73 and CD39 is antigen-independent and
linked to tissue localization. T cells in the salivary gland were
particularly likely to express all 3 molecules and were inhibited
by PD-1. In contrast, kidney localized T cells were less likely to
express these molecules, but were inhibited by CD73.
It is well-known that CD8+ T cells are not effective at
controlling MCMV in the salivary gland (8) and that CD4+ T
cells are needed in the salivary gland to control replicating
MCMV, presumably through their production of IFN-g (37,
68). In fact, CD8+ T cells in the salivary gland appear to develop
into resting, tissue-resident cells despite the ongoing viral
replication in this tissue. We previously showed that CD8+ T
cells that entered the salivary gland stopped dividing earlier than
circulating CD8+ T cells in the same mice and differentiated into
TRM cells during the height of viral replication in this tissue (13).
The development of TRM occurred in a TGF-b-dependent
manner (14) and (Supplemental Figures 5A, B) and the pace
of TRM formation was completely unaffected by virus in the
salivary gland (15). Our data shown here indicate that that these
T cells also exhibit reduced granzyme B expression relative to
their counterparts in the spleen (Supplemental Figure 8A).
Thus, these cells rapidly develop the phenotype that appears to
be resting despite the ongoing viral replication. This ﬁnding
suggests that the T cell behavior is partly the result of salivary
gland localization, rather than the MCMV infection. Consistent
with this, CD8+ T cells responding to Vaccinia virus, or that were
activated in vitro also expressed PD-1, CD73 and CD39 in the
salivary gland (Figure 2). This is likely relevant across infections
since activated T cells migrate freely into the salivary gland where
they become TRM (13–15, 38, 69).
Our data further suggest that PD-1, CD73 and CD39
expression was governed by tissue localization rather than
antigen. For PD-1, expression was retained on PD-1+ T cells
that entered the salivary gland, but not induced by antigen, tissue
localization or TGF-b signaling (Figures 2, 3). This extends our
previous work showing that virus-speciﬁc T cells that had
migrated into a tumor retained an intermediate level of PD-1
in an antigen-independent manner (46), a ﬁnding that has been
replicated in humans (70). Other labs have found that TRM cells
can express PD-1 in other tissues (44, 50–53), and the Lukacher
lab showed that PD-1 expression on brain TRM was retained in

Speciﬁc Killing of PD-L1-Expressing
Targets Within the Salivary Gland Is
Unaffected by PD-L1 Blockade
To assess speciﬁc killing of cells injected into the gland, we
labeled SIINFEKL-pulsed splenocytes with CellTrace Far Red
dye and mixed these target cells with an equal number of cells
labeled with CFSE, but loaded with the B8R peptide from VV as a
control. Speciﬁc killing of SIINFEKL-pulsed targets as assessed
by ﬂow cytometry was low and quite variable (Supplemental
Figure 8C). In contrast, killing of intravenously-injected targets
in the spleen was nearly 100% in all mice. However, histological
analyses of injected cells revealed that their dispersal into the
salivary gland was very uneven and that they preferentially
accumulated in the channels between lobules of the gland,
where T cells were not identiﬁed (Supplemental Figure 8D).
In these sites, as might be expected, target cells loaded with the
SIINFEKL peptide were not effectively killed (Supplemental
Figure 8D). These data suggest that the low overall killing of
injected cells as assessed by ﬂow cytometry, may relate to the
uneven distribution of targets and the presence of targets in T
cell-free channels. Remarkably however, SIINFEKL-loaded
target cells were obviously reduced in the E-cadherinexpressing areas of the gland (Supplemental Figure 8D, right
panels). We have previously shown that MCMV speciﬁc TRM
accumulate in and around these E-cadherin-positive cells (13).
Therefore, to assess the true ability of salivary gland T cells to kill
the injected targets, we analyzed speciﬁc killing histologically,
and only counted target or control cells that had inﬁltrated
regions of the salivary gland that expressed E-cadherin,
indicating epithelial cells. Using this approach, the data show
that target cells localized to E-cadherin-positive regions were
killed more effectively, but this was unchanged by PD-L1
blockade (Figure 7E). It is important to note however, that the
levels of killing were still below those found within the spleen
(compare to Supplemental Figure 8C). Together, our data show
while blocking PD-L1 in vivo improves the effector functions of
salivary gland-localized T cells, including improved cytokine
production, degranulation and granzyme B expression, it does
not impact the ability of these T cells to kill peptide-loaded
splenocytes that express PD-L1. Moreover, the most relevant
acinar epithelial cells rarely express PD-L1.
Collectively, our data suggest that tissue-localized T cells
express inhibitory molecules as part of tissue residency.
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(Figures 7C, D). However, these effects were only evident shortly
after the primary infection and PD-L1-expressing targets were
killed equally well within the salivary gland with or without PDL1 blockade (Figures 7C, E). These data could suggest that PD-1
is not markedly impairing the function of T cells within the
salivary gland environment, especially at late times post
infection. However, it is also possible that PD-1 is part of a
redundant set of inhibitory mechanisms that collectively impair
T cell function and/or that the impact of PD-1 is relatively subtle
and only apparent when the target cells are hard to kill. This last
idea is intriguing since viral immune evasion of MHC-I antigen
presentation makes infected cells hard to kill (79–82). While we
did not observe an effect of PD-L1 blockade on viral titers in the
salivary gland, our data suggest that this pathway will contribute
to T cell inhibition in other settings.
We believe that one of the most important additional
implications these data is the notion that ex vivo assays for T
cell function may be markedly affected by the tissue from which
the cells are recovered and may not faithfully report on the true T
cell function. We have found that purifying the salivary gland T
cells through a discontinuous Percoll layer (see materials and
methods) improved their function compared to stimulations of T
cells within the salivary gland homogenate (not shown), which
was the approach used by Hoffman and Pircher (38). Moreover,
the choice of APCs used in the in vitro assay likely plays a
signiﬁcant role in the outcome. In this study, as in previous work
from the Lukacher lab (44), we used DC2.4 cells as APCs. These
cells are PD-L1+ and are considered to be a dendritic cell line.
However, the impact of PD-1 was less evident when we used a
ﬁbroblast cell line (M2-10B4) that was treated with IFN-g to
induce expression of PD-L1 (not shown). Despite conﬁrmation
of PD-L1 on these cells, there are likely a large number of
differences in the expression of antigen presentation and costimulation machinery when compared to DC2.4s. For these
reasons, it will be critical to test the function of non-lymphoid T
cells after puriﬁcation and with a variety of APCs, or in vivo
whenever possible, before drawing conclusions about
their abilities.
We also tested the function of CD73 in suppressing T cell
function. Together, CD73 and CD39 convert extracellular ATP
to adenosine, which is an immune suppressive mechanism used
by regulatory T cells (75, 76). In contrast to blockade of the PD1/PD-L1 pathway, we did not observe an in vitro or in vivo effect
of blocking CD73 on salivary gland T cells. However, we did
observe improved function of T cells derived from the kidneys
and spleen. Again, restoration of T cell function required pretreatment of the mice with CD73 blocking antibody
(Figures 6D, F), indicating that CD73-induced suppression
was occurring in vivo and not an artifact of the culture
conditions. This result is striking since extracellular adenosine,
particularly adenosine generated by CD73, is well-known to play
critical physiological roles in the kidney (83). Indeed, CD73
enzymatic activity has been reported to be exceptionally high in
kidneys (84, 85). Therefore, it is an intriguing possibility that the
physiological function of CD73 in the kidney results in
constitutive adenosine-driven suppression of T cells in this

an antigen-independent manner (44). Collectively, these data are
striking since PD-1 is well-described to be silenced in the absence
of ongoing antigen stimulation. Repression of PD-1 is induced by
the B-lymphocyte-induced maturation protein-1 (Blimp-1),
which alters transcription factor binding in the pdcd1 (PD-1)
gene promoter and promotes repressive histone methylation (71,
72) unless T cells are exposed to chronic antigen (73, 74). Thus,
together these data imply that repression of PD-1 fails to occur in
some non-lymphoid tissues and it will be interesting to
determine whether the repressive methylation of the pdcd1
promoter is impaired in salivary gland or kidney-localized T
cells, or T cells in other tissues.
It was also surprising that tissue-localized T cells, particularly
those in the salivary gland, expressed both CD39 and CD73. Both
regulatory T cells (TREG) and TH17 cells are known to express
CD39 and CD73 (75–78) and this expression is associated with
immune suppressive function of both populations through the
production of adenosine in the environment. Expression of
CD73 on CD8+ T cells in the salivary gland and kidney (as
well as the spleen) was induced by TGF-b signaling (Figure 3),
which is consistent with previous work on TREG (63). Since
TGF-b is also vital for the formation of TRM (14, 59–62) and
(Supplemental Figures 5A, B), these data link the TRM program
to the expression of the suppressive CD73 molecule.
Interestingly, TGF-b was not required for CD39 expression in
the salivary gland T cells despite being implicated in the
expression of CD39 on TH17 cells (77). Thus, together, our
data suggest that both PD-1 and CD73 expression by CD8+ cells
was governed by tissue localization in distinct ways.
It was previously shown by Hofmann and Pircher that T cells
recovered from the salivary gland functioned poorly in ex vivo
stimulation assays (38). Likewise, when compared to T cells
recovered from the spleen or lung with the same TCR, a smaller
percentage of CD8+ T cells from the salivary gland made IFN-g
or degranulated upon stimulation (14) and (Figures 4A–C).
These data raised the possibility that these inhibitory molecules
might be contributing to the reduced T cell function and thus,
the failure of CD8+ T cells to control MCMV in the salivary
gland. However, blockade of PD-L1 and/or CD73 had no effect
on viral load in the salivary gland (Figure 6D). Nevertheless, PDL1 blockade in vivo prior to T cell recovery improved the
function of these T cells ex vivo (Figure 4F). Interestingly, the
Pircher lab also showed that salivary gland-localized T cells could
better secrete IFN-g when the stimulating peptide was injected
intravenously (38). We also found that more T cells produced
cytokine after i.v. injection of the peptide (Figure 6F). However,
PD-L1 blockade had no discernable effect in this setting. It must
be noted that this approach will load peptide on a multitude of
potential targets and antigen presenting cells. In the salivary
gland and kidney, most of the non-hematopoietic cells lack PDL1 (Figure 7A) and thus may not be able to engage this
inhibitory pathway. For this reason, we also tested direct intraglandular injections of peptide-pulsed splenocytes, nearly all of
which express PD-L1 (Figure 7A). These data revealed that PDL1 blockade could modestly improve the induction of Granzyme
B and possibly enhance T cell proliferation after stimulation
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tissue and in contrast to other tissues. Much less is known about
the function of CD73 and extracellular adenosine in the salivary
gland. It is possible that extracellular ATP was rarely released in
our experimental conditions and therefore that CD39 and CD73
rarely converted it to adenosine. However, again, there may be
settings in which this pathway is engaged, resulting in adenosinemediated inhibition of local T cells. Future work will need to
address these issues.
Overall, our data show that the inhibitory molecules PD-1,
CD73 and CD39 are part of tissue-localization for T cells in the
salivary gland and kidney and are sustained (PD-1) or expressed
(CD73) in an antigen-independent manner. The expression of
PD-1, but not CD73, resulted in inhibition of T cells in the
salivary gland, but the impact was modest and context dependent
and did not prevent T cells from killing PD-L1 expressing targets
within the salivary gland environment. In contrast, kidney
localized T cells were inhibited by CD73, but not PD-1.
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